Stock 002821 ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Asymchem Laboratories (Tianjin) Co., Ltd.

Equities

002821

CNE100002BZ6

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
82.65 CNY -1.82% Intraday chart for Asymchem Laboratories (Tianjin) Co., Ltd. +7.66% -28.81%
Apr. 29 Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3% MT
Apr. 26 Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 29,964 72,546 111,228 52,704 41,387 28,893 - -
Enterprise Value (EV) 1 29,964 72,546 105,428 47,553 34,424 22,600 20,801 19,720
P/E ratio 54 x 97.1 x 99.1 x 16.4 x 18.5 x 24.9 x 17.5 x 15.1 x
Yield 0.39% 0.2% 0.18% 1.22% 1.55% 0.83% 1.02% 1.21%
Capitalization / Revenue 12.2 x 23 x 24 x 5.15 x 5.32 x 4.48 x 3.74 x 3.06 x
EV / Revenue 12.2 x 23 x 22.8 x 4.65 x 4.42 x 3.51 x 2.69 x 2.09 x
EV / EBITDA 40 x 74.3 x 83.1 x 13.6 x 9.5 x 13.7 x 9.59 x 7.42 x
EV / FCF - -163 x -68.2 x 41.8 x 14.7 x -328 x 26 x 20 x
FCF Yield - -0.61% -1.47% 2.39% 6.82% -0.31% 3.84% 5%
Price to Book 9.84 x 12.1 x 9.07 x 3.5 x 2.46 x 1.69 x 1.57 x 1.42 x
Nbr of stocks (in thousands) 323,935 339,521 368,307 364,755 364,426 357,344 - -
Reference price 2 92.50 213.7 310.7 148.0 116.1 82.65 82.65 82.65
Announcement Date 2/28/20 4/15/21 3/30/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,460 3,150 4,632 10,230 7,781 6,447 7,729 9,454
EBITDA 1 748.6 976.8 1,269 3,498 3,623 1,645 2,169 2,659
EBIT 1 623.7 816.9 1,068 3,136 2,236 1,277 1,735 2,170
Operating Margin 25.35% 25.94% 23.05% 30.65% 28.73% 19.81% 22.45% 22.95%
Earnings before Tax (EBT) 1 623.6 814.4 1,193 3,725 2,557 1,400 1,835 2,290
Net income 1 553.9 722.1 1,069 3,302 2,269 1,247 1,728 2,020
Net margin 22.51% 22.93% 23.08% 32.27% 29.16% 19.34% 22.35% 21.37%
EPS 2 1.714 2.200 3.136 9.000 6.260 3.326 4.725 5.465
Free Cash Flow 1 - -445.6 -1,547 1,136 2,347 -69 799.2 986.5
FCF margin - -14.15% -33.39% 11.11% 30.16% -1.07% 10.34% 10.43%
FCF Conversion (EBITDA) - - - 32.49% 64.79% - 36.85% 37.1%
FCF Conversion (Net income) - - - 34.42% 103.45% - 46.26% 48.83%
Dividend per Share 2 0.3571 0.4286 0.5714 1.800 1.800 0.6854 0.8411 0.9995
Announcement Date 2/28/20 4/15/21 3/30/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 S2 2022 S1 2022 Q3 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2
Net sales 1 2,879 5,034 2,770 5,198 2,249 2,350 4,596 1,762 1,437 3,186 1,400 1,451 2,815 1,595 1,845 3,441 2,203 2,324
EBITDA - - - - - - - - - - - - - - - - - -
EBIT 1 710.6 1,699 - 1,464 - 952 1,670 559.8 - 565.4 - 266.1 447.5 212.8 275.3 488 - -
Operating Margin 24.69% 33.74% - 28.17% - 40.52% 36.35% 31.78% - 17.75% - 18.33% 15.9% 13.34% 14.92% 14.18% - -
Earnings before Tax (EBT) - - - - - - - 559.6 - - - - - - - - - -
Net income - - 980.8 - - - - 523.7 - - - - - - - - - -
Net margin - - 35.41% - - - - 29.73% - - - - - - - - - -
EPS - - - - 1.720 - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - -
Announcement Date 3/30/22 8/25/22 10/27/22 3/30/23 4/28/23 8/29/23 8/29/23 10/30/23 3/28/24 3/28/24 4/25/24 - - - - - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - 5,800 5,151 6,963 6,293 8,092 9,173
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -446 -1,547 1,136 2,347 -69 799 986
ROE (net income / shareholders' equity) 19.9% 18.2% 12.1% 23.4% 13.9% 6.76% 8.65% 9.51%
ROA (Net income/ Total Assets) 16% 13.2% 10.1% 19.8% 12.1% 5.96% 7.17% 8.12%
Assets 1 3,472 5,458 10,635 16,698 18,729 20,930 24,096 24,894
Book Value Per Share 2 9.400 17.70 34.20 42.30 47.30 48.90 52.60 58.30
Cash Flow per Share 2 1.850 1.680 3.310 8.960 9.600 4.780 4.450 5.470
Capex 1 511 1,015 1,660 2,151 1,203 1,209 1,278 1,363
Capex / Sales 20.76% 32.22% 35.83% 21.02% 15.46% 18.75% 16.54% 14.42%
Announcement Date 2/28/20 4/15/21 3/30/22 3/30/23 3/28/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
82.65 CNY
Average target price
99.42 CNY
Spread / Average Target
+20.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. Stock Asymchem Laboratories (Tianjin) Co., Ltd.
-28.81% 4.06B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.29% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.95% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.79% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 196B
AMGEN INC. Stock Amgen Inc.
-4.89% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002821 Stock
  4. Financials Asymchem Laboratories (Tianjin) Co., Ltd.